证券代码：603122 证券简称：合富中国 公告编号：临 2025-011 合富（中国）医疗科技股份有限公司 关于公司向银行等金融机构申请授信额度的议案 授信额度：不超过 15 亿元。 额度期限：自合富（中国）医疗科技股份有限公司（以下简称"公司"） 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会召开之日 内有效。 司需要且对公司最为有利的条件来操作。 申请授信和办理贷款融资等业务时，公司董事会提请股东大会授权法定代 表人或法定代表人指定的授权代理人全权代表公司签署上述授信额度内的一切 与授信(包括但不限于授信、融资等)有关的合同、协议等各项法律文件。 特此公告。 合富（中国）医疗科技股份有限公司董事会 本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 3 月 11 日召开了第二届董事会第十四次会议，审议通过了 《关于公司向银行等金融机构申请授信额度的议案》，现将相关事项公告如下： 根据公司 2024 年向银行等金融机 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-007 合富（中国）医疗科技股份有限公司 关于 2024 年度募集资金存放与实际使用情况的专项报告 本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074号）核准，合富（中国） 医疗科技股份有限公司（以下简称"公司"）首次向社会公开发行人民币普通股 （A股）股票9,951.32万股，本次发行价格为每股人民币4.19元，募集资金总额 为人民币416,960,308.00元，扣除发行费用人民币（不含增值税）57,269,314.59 元后，实际募集资金净额为人民币359,690,993.41元。本次发行募集资金已于 2022年2月11日全部到位，并经毕马威华振会计师事务所（特殊普通合伙）审验， 于2022年2月11日出具了《验资报告》（ ...

公司代码：603122 公司简称：合富中国 合富（中国）医疗科技股份有限公司 2024 年度内部控制评价报告 合富（中国）医疗科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外， ...

合富（中国）医疗科技股份有限公司 募集资金 2024 年度存放与实际使用情况专项报告的鉴证报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 对合富（中国）医疗科技股份有限公司 募集资金 2024 年度存放与实际使用情况专项报告的鉴证报告 毕马威华振专字第 2500691 号 合富（中国）医疗科技股份有限公司董事会： 我们接受委托，对后附的合富（中国）医疗科技股份有限公司（以下简称"贵公 司"） 募集资金 2024 年度存放与实际使用情况的专项报告（以下简称"专项报告"）执 行了合理 ...

本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 重要内容提示： 投资种类：保本型理财产品。 投资金额：最高额度不超过人民币 3 亿元，在该额度范围内，资金可循 环滚动使用。 履行的审议程序：合富（中国）医疗科技股份有限公司（以下简称"公 司"）于 2025 年 3 月 11 日召开第二届董事会第十四次会议，审议通过了《关于 公司使用暂时闲置自有资金进行委托理财的议案》，同意使用最高额度不超过人 民币 3 亿元的闲置自有资金购买理财产品，额度使用期限自董事会审议通过之 日起一年内有效，在前述额度及期限范围内资金可循环滚动使用，实现资金的 保值和增值。 证券代码：603122 证券简称：合富中国 公告编号：临 2025-012 合富（中国）医疗科技股份有限公司 关于公司使用暂时闲置自有资金进行委托理财的公告 特别风险提示：公司拟购买的理财产品品种主要是保本型的理财产品， 但金融市场受宏观经济的影响较大，不排除该项投资受到市场波动风险、宏观 经济形势及货币政策、财政政策等宏观政策 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-005 合富（中国）医疗科技股份有限公司 第二届董事会第十四次会议决议公告 本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担法律责任。 重要内容提示： 独立董事 Stanley Yi Chang 先生因个人身体健康原因未能出席本次董事 会会议。 一、董事会会议召开情况 本议案尚需提交股东大会审议，股东大会召开时间另行通知。 2、审议并通过了《关于公司 2024 年度董事会工作报告的议案》。 表决结果：6 票赞成，0 票反对，0 票弃权。 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会第 十四次会议于 2025 年 3 月 11 日上午在上海市虹漕路 456 号光启大楼 20 楼公司 董事会议室/台北市敦化南路 2 段 76 号 23 楼以现场与视讯相结合的方式召开， 会议通知于 2025 年 2 月 28 日以电子邮件或书面方式发出。本次会议由董事长李 惇先生主持，应到董事 7 人，实到董事 6 人， ...

Financial Performance - The company's operating revenue for 2024 was CNY 939,140,060.58, a decrease of 14.05% compared to CNY 1,092,602,026.63 in 2023[24]. - Net profit attributable to shareholders for 2024 was CNY 27,566,297.58, down 41.58% from CNY 47,186,921.09 in 2023[24]. - Basic earnings per share for 2024 decreased to CNY 0.07, a decline of 41.67% from CNY 0.12 in 2023[25]. - The weighted average return on equity for 2024 was 2.37%, down 1.69 percentage points from 4.06% in 2023[25]. - The gross margin for the main business was 19.59%, a decrease of 1.11 percentage points from the previous year[58]. - Revenue from the core in vitro diagnostic product business was CNY 879.53 million, down 14.87% year-on-year[58]. - The company reported a total revenue of CNY 939.14 million, a decrease of 14.05% year-on-year[53]. - Net profit attributable to shareholders was CNY 27.57 million, down 41.58% compared to the previous year[53]. - Operating cash flow increased significantly to CNY 132.75 million, up 1,076.77% year-on-year[55]. Dividend and Shareholder Matters - The board proposed a cash dividend of CNY 0.50 per share (including tax), totaling approximately CNY 19.90 million, subject to shareholder approval[6]. - The company does not plan to increase capital reserves or issue bonus shares[6]. - The company has not proposed a cash profit distribution plan for the reporting period, as the retained earnings will be used for future investments[140]. - The board of directors has approved the cash dividend proposal, which is pending approval from the shareholders' meeting[138]. - The total cash dividend distributed over the last three accounting years amounts to RMB 103,493,684.58, with an average annual net profit of RMB 52,490,962.16, resulting in a cash dividend ratio of 197.16%[143]. Governance and Compliance - The company has established a governance framework that includes a shareholders' meeting, board of directors, and supervisory board, ensuring clear responsibilities and effective operation[97]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, and financial management, ensuring a complete business system[99]. - The company has implemented a robust internal control management system, maintaining effective financial reporting controls without significant deficiencies[98]. - The company has not encountered any major legal violations or penalties during the reporting period, adhering strictly to relevant laws and regulations[98]. - The company has established a remuneration and assessment committee to evaluate the performance of directors and senior management, ensuring accountability and effective governance[145]. Market and Competitive Landscape - The domestic in vitro diagnostic market has surpassed 100 billion RMB, with continuous growth expected due to rising health awareness and an aging population[39]. - The competitive landscape in the in vitro diagnostic sector is intensifying, with increased market participants leading to potential price wars and heightened marketing competition[40]. - The company’s revenue and profit have declined compared to 2023 due to tightened procurement budgets from hospital clients and intensified market competition[34]. - The company aims to enhance its comprehensive service capabilities in the competitive in vitro diagnostics market, focusing on logistics, maintenance, and value-added services[85]. Strategic Initiatives and Innovations - The company has developed the "Zhibeita" integrated decision analysis platform, which aims to enhance hospital operational performance through data integration and real-time reporting, responding to national policies requiring hospitals to have operational management tools[43]. - The company is actively seeking and expanding projects that provide differentiated services, including AI-assisted clinical diagnosis systems[35]. - The company has launched an intelligent reagent and consumable management platform to help hospitals manage costs and improve efficiency, resulting in increased customer loyalty[37]. - The company is shifting from a trading and service provider to a comprehensive smart medical solution provider, focusing on self-owned product expansion and digital services[92]. Risk Factors - The company faces risks from intensified market competition in the in vitro diagnostics industry, which could adversely affect production and profitability if product layout and service networks are not continuously improved[94]. - The company is exposed to risks related to the lack of a controlling shareholder, which may lead to instability in governance and inefficiencies in major business decisions[94]. - A new round of centralized procurement for in vitro diagnostic reagents has been initiated, involving 28 provinces, which may impact revenue and gross margins if the company fails to adapt[94]. Environmental and Social Responsibility - The company has implemented various environmental management measures, including energy-saving policies and waste management regulations, to enhance its environmental responsibility[151]. - The company actively engages in social responsibility initiatives, including volunteer services and donations, although specific financial contributions were not detailed[155]. - The company has committed to supporting poverty alleviation and rural revitalization projects, with specific details on financial inputs and beneficiaries not provided[156]. Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 203, with 122 in the parent company and 81 in subsidiaries[127]. - The company has established a comprehensive employee training system, including mandatory training for all new employees and specialized training for various roles[131]. - The company emphasizes the importance of employee training and has developed an online learning platform for skill enhancement[131]. - The company’s compensation policy includes fixed salaries and performance bonuses, with a focus on industry standards and local living costs[129].